1. Home
  2. GDOT vs ALLO Comparison

GDOT vs ALLO Comparison

Compare GDOT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GDOT
  • ALLO
  • Stock Information
  • Founded
  • GDOT 1999
  • ALLO 2017
  • Country
  • GDOT United States
  • ALLO United States
  • Employees
  • GDOT N/A
  • ALLO N/A
  • Industry
  • GDOT Finance: Consumer Services
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GDOT Finance
  • ALLO Health Care
  • Exchange
  • GDOT Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • GDOT 363.9M
  • ALLO 371.8M
  • IPO Year
  • GDOT 2010
  • ALLO 2018
  • Fundamental
  • Price
  • GDOT $9.67
  • ALLO $1.34
  • Analyst Decision
  • GDOT Hold
  • ALLO Strong Buy
  • Analyst Count
  • GDOT 3
  • ALLO 9
  • Target Price
  • GDOT $10.33
  • ALLO $8.44
  • AVG Volume (30 Days)
  • GDOT 972.6K
  • ALLO 4.1M
  • Earning Date
  • GDOT 05-08-2025
  • ALLO 05-13-2025
  • Dividend Yield
  • GDOT N/A
  • ALLO N/A
  • EPS Growth
  • GDOT N/A
  • ALLO N/A
  • EPS
  • GDOT N/A
  • ALLO N/A
  • Revenue
  • GDOT $1,825,327,000.00
  • ALLO N/A
  • Revenue This Year
  • GDOT $19.42
  • ALLO N/A
  • Revenue Next Year
  • GDOT $11.26
  • ALLO $10.02
  • P/E Ratio
  • GDOT N/A
  • ALLO N/A
  • Revenue Growth
  • GDOT 18.98
  • ALLO N/A
  • 52 Week Low
  • GDOT $6.13
  • ALLO $0.86
  • 52 Week High
  • GDOT $13.58
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • GDOT 54.46
  • ALLO 49.26
  • Support Level
  • GDOT $8.98
  • ALLO $1.10
  • Resistance Level
  • GDOT $9.39
  • ALLO $1.15
  • Average True Range (ATR)
  • GDOT 0.32
  • ALLO 0.11
  • MACD
  • GDOT -0.08
  • ALLO 0.02
  • Stochastic Oscillator
  • GDOT 18.43
  • ALLO 93.75

About GDOT Green Dot Corporation $0.001 par value

Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for today's workforce.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: